Clinical trial
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That…
NCT00335829 · Yale University, Other · Completed
Key facts
| NCT number | NCT00335829 |
|---|---|
| Title | Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery |
| Official title | Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma |
| Lead sponsor | Yale University, Other |
| Collaborators | National Cancer Institute (NCI) NIH Northwestern University |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | bevacizumab, chemotherapy, embolization therapy, hepatic artery infusion |
| Enrollment | 26 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Jun 12, 2006 |
| Last update posted | Aug 13, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: